# Oral Abuse Potential Study of Nalbuphine

> **NCT04018664** · PHASE1 · COMPLETED · sponsor: **Trevi Therapeutics** · enrollment: 56 (actual)

## Conditions studied

- Nalbuphine
- Opioid Abuse

## Interventions

- **DRUG:** Nalbuphine HCl solution
- **DRUG:** Placebo solution

## Key facts

- **NCT ID:** NCT04018664
- **Lead sponsor:** Trevi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-29
- **Primary completion:** 2018-12-03
- **Final completion:** 2020-06-02
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04018664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04018664, "Oral Abuse Potential Study of Nalbuphine". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT04018664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*